Several studies are previously conducted to discover the role of lncRNA MALAT1 in chemoresistance, however, how MALAT1 functions in the context of a therapeutic approach with special prominence to MALAT1/STAT3 and MALAT1/FUT4 axis in paclitaxel-resistant lung cancer is not well-known. Here, STAT3 is linked to lung carcinoma.